

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**TYK Medicines, Inc**

**浙江同源康醫藥股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2410)**

## **INSIDE INFORMATION**

### **GRANT OF LISTING APPROVAL BY THE STOCK EXCHANGE FOR IMPLEMENTATION OF THE H SHARE FULL CIRCULATION**

This announcement is made by TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**Inside Information Provisions**”).

References are made to (i) the announcement of the Company dated June 6, 2025 in relation to the application for the H share full circulation by the Company; and (ii) the announcement of the Company dated January 23, 2026 in relation to the issuance of the Filing Notice by the CSRC for the H share full circulation application of the Company (collectively, the “**Announcements**”). Unless otherwise stated, terms used herein shall have the same meanings as those defined in the Announcements.

#### **LISTING APPROVAL BY THE STOCK EXCHANGE**

The Board of the Company is pleased to announce that the Company has applied to the Listing Committee of the Stock Exchange for the approval (the “**Listing Approval**”) of the listing of 4,608,000 H shares (the “**Converted H Shares**”) of the Company to be converted under the conversion of 4,608,000 Unlisted Shares (the “**Conversion**”) held by 1 shareholder of the Company (the “**Listing**”) and the permission to deal in the Converted H Shares. The Company is pleased to announce that the Listing Approval was granted by the Stock Exchange on February 11, 2026.

## Shareholding Structure

The Conversion and the Listing will involve a total of 1 participating shareholder of 4,608,000 Unlisted Shares and the number of the Converted H Shares held by such participating shareholder represents approximately 1.21% of the total issued shares of the Company as at the date of this announcement.

Set out below is the percentage holding in the Company in relation to the participating shareholder of the Unlisted Shares upon completion of the Conversion and the Listing.

Name of shareholder	Number of Unlisted Shares to be converted into H Shares	Approximate percentage <sup>(1)</sup> of the Company's total issued share capital <sup>(2)</sup>
Zhuzhou Guohai Guochuang Qianjin Pharmaceutical Venture Capital Partnership (Limited Partnership)*/ 株洲市國海國創千金醫藥創業投資合夥企業(有限合夥)	4,608,000	1.21%
<b>Total</b>	<b>4,608,000</b>	<b>1.21%</b>

Note:

- (1) The percentages have been rounded up to the nearest two decimal places.
- (2) The calculation is based on the total number of 380,065,818 shares of the Company in issue as of the date of this announcement.

As at the date of this announcement and upon completion of the Conversion and the Listing, the share capital structure of the Company will be as follows:

Class of shares	As at the date of this announcement		Upon completion of the Conversion and the Listing	
	<i>Number of share</i>	<i>Approximate percentage %</i>	<i>Number of share</i>	<i>Approximate percentage %</i>
H shares	375,457,818	98.79%	380,065,818	100.00%
Unlisted shares	4,608,000	1.21%	—	—
<b>Total</b>	<b>380,065,818</b>	<b>100.00%</b>	<b>380,065,818</b>	<b>100.00%</b>

Note: The percentages have been rounded up to the nearest two decimal places and any discrepancy between the totals and sums of amounts listed in the table is due to rounding.

The Company shall complete the relevant conversion and trading procedures in respect of the Converted H Shares and will make further announcement(s) on the progress of the Conversion and the Listing in compliance with the requirements under the Listing Rules and applicable laws, as and when appropriate.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the H shares of the Company.**

By Order of the Board  
**TYK Medicines, Inc**  
(浙江同源康醫藥股份有限公司)

**Dr. WU Yusheng**

*Chairman, Executive Director and Chief Executive Officer*

Hong Kong, February 12, 2026

*As at the date of this announcement, the Board comprises Dr. WU Yusheng as executive Director, Dr. LI Jun, Dr. GU Eric Hong, Dr. JIANG Mingyu, Mr. HE Chao and Dr. ZHU Xiangyang as non-executive Directors, and Dr. LENG Yuting, Dr. XU Wenqing, Dr. SHEN Xiuhua and Mr. JIANG Xiaolin as independent non-executive Directors.*